In this study , we assessed the efficacy of 2 pharmacodynamically different antidepressants , citalopram ( a selective serotonin reuptake inhibitor ) and reboxetine ( a norepinephrine reuptake inhibitor ) , as adjunctive therapy to risperidone and olanzapine for the treatment of negative symptoms in schizophrenia .